- Home
- Training
-
- Certification
-
At a glance
The CPM programs are designed to lead your organisation towards a higher pricing maturity level.Calendar
Certification Programs
Alumni
A global community of pricing leaders with a proven record of succesful pricing project delivery.Your learning partner
-
- Events
-
EPP Forums
We leverage our expertise and partner with top tier pricing and revenue growth management experts, practitioners and solution providers to bring you the most relevant and actionable insights and networking during the EPP events.
EPP Global Pricing Forum
Our yearly global flagship conference where we bring cross-industrial actionable insights to boost your roadmaps.
Industry Forums
Online Events
Endorsed Partner Events
EPP endorses recommended pricing events organised by our partners.
-
- Resources
-
- Journals
- EPP Prime
- Partners
In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL).
This year, PD-1 inhibitors — a category of drugs that are often costly yet highly effective — were the hot issue between multinational corporations (MNCs) and domestic businesses. When the negotiations came to a close, home-grown PD-1 efforts from Shanghai Junshi Biosciences, BeiGene Ltd. and Jiangsu Hengrui Medicine took the coveted spots from household names like Roche, Bristol Myers Squibb, AstraZeneca and MSD.
